Evidence map›Paper›PMID 26551697›Full record

ReviewBiochemical Society transactions2015

The methodology of TSPO imaging with positron emission tomography.

Federico E Turkheimer, Gaia Rizzo, Peter S Bloomfield, Oliver Howes, Paolo Zanotti-Fregonara, Alessandra Bertoldo, Mattia Veronese

Registry-linked trialAbstract readReview
In one paragraph

Review in Biochemical Society transactions, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03702816 (The Relationship Between Neuropsychological Testing and MRI, PET and Blood Biomarkers in Neurodegenerative Disease), which is not on this map. Cited by 145 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 2 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03702816 phase2terminatednot on this mapstarted 2018, after this paper: background citation

The Relationship Between Neuropsychological Testing and MRI, PET and Blood Biomarkers in Neurodegenerative Disease (COBRE - Project 1): AIM 2

TypeinterventionalSponsorAaron Ritter, MDRan2018 to 2019Enrolled24ConditionsAlzheimer Disease, Parkinson Disease, InflammationArmsGE180 PET Scan
3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 2 syntheses or guidelines pooled it, 229 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Trial
  4. Trial
  5. Trial
  6. Kinetic modelling of [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018
    Trial
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. First evaluation in multiple sclerosis using PET tracer [European journal of nuclear medicine and molecular imaging · 2026
    Article
  17. Article
  18. Article
  19. Review
  20. Review

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Federico E TurkheimerInstitute of Psychiatry, King's College London, London SE5 8AF, U.K. federico.turkheimer@kcl.ac.uk.
Gaia RizzoInformation Engineering Dept., University of Padova, Padova 35131, Italy.
Peter S BloomfieldInstitute of Clinical Sciences, Imperial College London, London W12 0NN, U.K.
Oliver HowesInstitute of Psychiatry, King's College London, London SE5 8AF, U.K. MRC Institute of Clinical Sciences, Imperial College London, U.K.
Paolo Zanotti-FregonaraUniversity of Bordeaux, CNRS, INCIA, UMR 5287, France.
Alessandra BertoldoInformation Engineering Dept., University of Padova, Padova 35131, Italy.
Mattia VeroneseInstitute of Psychiatry, King's College London, London SE5 8AF, U.K.
University of Padua · ITInstitut de Neurosciences Cognitives et Intégratives d’Aquitaine · FR

Funding

Medical Research Council G1100809Medical Research Council G1100809/1Medical Research Council MC_U120097115Wellcome Trust
6 · The paper itself

Abstract

The 18-kDA translocator protein (TSPO) is consistently elevated in activated microglia of the central nervous system (CNS) in response to a variety of insults as well as neurodegenerative and psychiatric conditions. It is therefore a target of interest for molecular strategies aimed at imaging neuroinflammation in vivo. For more than 20 years, positron emission tomography (PET) has allowed the imaging of TSPO density in brain using [(11)C]-(R)-PK11195, a radiolabelled-specific antagonist of the TSPO that has demonstrated microglial activation in a large number pathological cohorts. The significant clinical interest in brain immunity as a primary or comorbid factor in illness has sparked great interest in the TSPO as a biomarker and a surprising number of second generation TSPO radiotracers have been developed aimed at improving the quality of TSPO imaging through novel radioligands with higher affinity. However, such major investment has not yet resulted in the expected improvement in image quality. We here review the main methodological aspects of TSPO PET imaging with particular attention to TSPO genetics, cellular heterogeneity of TSPO in brain tissue and TSPO distribution in blood and plasma that need to be considered in the quantification of PET data to avoid spurious results as well as ineffective development and use of these radiotracers.

Indexed as

HumansIsoquinolinesMicrogliaPositron-Emission TomographyReceptors, GABAIsoquinolinesPK 11195Receptors, GABATSPO protein, humanendotheliumgeneticsheterogeneitykinetic modellingmethodologymicroglianeuroinflammationperipheral benzodiazepine receptor (PBR)peripheral benzodiazepine receptor (PBR)28PK11195plasma free fractionpositron emission tomographyschizophreniatranslocator protein (TSPO)

Identifiers

PMID26551697
PMCPMC4613512
OpenAlexW2121010289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.